26 Lessons learned from complement inhibition in ANCA vasculitis

Abstract

and immune (e.g. systemic lupus erythematosus) 4 disorders, but underscored by the thrombotic diathesis associated with the rare but devastating genetic complement-mediated disorders, paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). 5 Both of these complement-mediated disorders that feature thrombosis, are extraordinarily responsive to treatment with a highly specific inhibitor of complement, highlighting the importance of delineating the relationship between complement and coagulation. Learning Objectives. Describe the cellular and molecular links between the complement and coagulation systems . Discuss the role of complement in different diseases . Explain the importance of delineating the relationship between complement and coagulation REFERENCES 1. Conway EM. Reincarnation of ancient links between coagulation and complement.

Lupus nephritis, 2022

“…A komplementútvonalon ható terápiákkal jelenleg elsősorban a szteroiddózis csökkentése/szteroidadás kiváltása irányába zajlanak vizsgálatok. Érdemes közülük kiemelni az ANCAvasculitisekben már elfogadott C5aR-gátló avacopant és az iptacopant, amellyel idén kezdődnek LN-t célzó vizsgálatok (24).…”